Swedish Orphan Biovitrum (Sobi) has entered into a definitive agreement to buy biopharmaceutical company CTI BioPharma in an all-cash deal valued at $1.7bn.

Sobi will start a tender offer through its wholly owned indirect subsidiary to buy all outstanding CTI shares for $9.10 for each share of common stock in cash.

The acquisition will strengthen Sobi’s haematology medicines portfolio with the addition of CTI’s lead product Vonjo (pacritinib), a novel oral kinase inhibitor of JAK2, IRAK1 and ACRV1.

The deal will also enhance the commercial footprint of Sobi in the US.

CTI is expected to benefit from the resources, scale and international presence of Sobi in expanding and investigating new indications and development opportunities for Vonjo.

CTI BioPharma president, CEO and interim chief medical officer Adam Craig stated: “We are delighted to announce this transaction, which delivers a compelling all-cash premium to our shareholders while positioning CTI to unlock the full potential of Vonjo in treating myeloproliferative disease.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“In Sobi, we’ve found a global partner whose mission, culture and strategic business priorities are aligned with ours, and by joining forces we have access to additional financial and development resources to drive and enhance the growth of Vonjo.”

Vonjo has received the US Food and Drug Administration’s approval to treat myelofibrosis in adult patients with a platelet count below 50 x109/L .

CTI’s board of directors has unanimously approved the transaction, which will be concluded in the third quarter of 2023.

The company will then become a wholly owned subsidiary of Sobi.